A clinical trial to determine the optimal timing of androgen deprivation in relapsed or non-curable prostate cancer
Grant number: 350201
The aim of the study is to clarify when is the optimal time to start hormone treatment for men with certain stages of prostate cancer. It has long been known that testosterone removal impedes prostate cancer growth, although not permanently. The removal of testosterone, however, has side effects , including loss of libido, hot flushes, weight gain, and in the longer term osteoporosis, loss of muscle bulk and mental changes such as loss of memory. Any benefit to be gained for a patient must therefore be weighed against these side effects. This is particularly relevant in situations in which cure is not possible, when the aim of treatment should be to manage symptoms (either by preventing or d..View full description
Related publications (3)
Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial
Gillian M Duchesne, Henry H Woo, Julie K Bassett, Steven J Bowe, Catherine D'Este, Mark Frydenberg, Madeleine King, Leo Ledwich, Andrew Loblaw, Shawn Malone, Jeremy Millar, Roger Milne, Rosemary G Smith, Nigel Spry, Martin Stockler, Rodney A Syme, Keen Hun Tai, Sandra Turner
BACKGROUND: Androgen-deprivation therapy is offered to men with prostate cancer who have a rising prostate-specific antigen after ..
The 'Timing of Androgen-Deprivation therapy in incurable prostate cancer' protocol (TOAD) where are we now? Synopsis of the Victorian Cooperative Oncology Group PR 01-03 and Trans-Tasman Radiation Oncology Group 03.06 clinical trial
Gillian M Duchesne, Henry H Woo
OBJECTIVE: To outline the development of the 'Timing of Androgen Deprivation' (TOAD) protocol, a collaborative randomised clinical..
Tribulations of a prostate cancer trial - Lessons learned from TOAD, a Cancer Council Victoria and Transtasman Radiation Oncology Group trial
Gillian M Duchesne, Henry H Woo, Deborah Howell, Mary Kaimakamis, Evan Kemp
From 2004–2009 a total of 226 out of a target of 750 prostate cancer patients have been randomised into the Timing of Androgen Dep..